Among these, PARP inhibitors have demonstrated efficacy, particularly for BRCA-related, high-grade ovarian cancer, BRCA-mutated breast cancer as well as triple negative breast cancer (TNBC). This evidence concerns the gene PARP1 and breast carcinoma.